About: Human Monoclonal Antibodies as Adjuvant Treatment of Chronic Hepatitis B Virus Infection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Human Monoclonal Antibodies as Adjuvant Treatment of Chronic Hepatitis B Virus Infection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Human Monoclonal Antibodies as Adjuvant Treatment of Chronic Hepatitis B Virus Infection
Creator	Cerino, Antonella Mantovani, Stefania Mele, Dalila Oliviero, Barbara Varchetta, Stefania Mondelli, Mario Thimme, Robert Yoon, Seung
Source	PMC
abstract	Despite the availability of an effective prophylactic vaccine leading to sterilizing immunity, hepatitis B virus (HBV) is responsible for chronic liver disease in more than 250 million individuals, potentially leading to cirrhosis and hepatocellular carcinoma. Antiviral drugs able to completely suppress virus replication are indeed available but they are, by and large, unable to eradicate the virus. Several alternative new treatment approaches are currently being developed but none have so far captured the interest of clinicians for possible clinical development. A constant feature of chronic HBV infection is T-cell exhaustion resulting from persistent exposure to high antigen concentrations as shown by the high expression of programmed cell death protein 1 (PD-1) by HBV-specific CD8 T cells. One way of tackling this problem is to develop HBV-specific neutralizing antibodies that would clear excess envelope proteins from the circulation, allowing for nucleos(t)ide analogs or other antiviral drugs now in preclinical and early clinical development to take advantage of a reconstituted adaptive immunity. Several fully human monoclonal antibodies (mAb) have been developed from HBV-vaccinated and subjects convalescent from acute hepatitis B that show different properties and specificities. It is envisaged that such neutralizing mAb may be used as adjuvant treatment to reduce viral protein load, thus rescuing adaptive immunity in an effort to optimize the effect of antiviral drugs.
has issue date	2019-09-25(xsd:dateTime)
bibo:doi	10.3389/fimmu.2019.02290
bibo:pmid	31608071
has license	cc-by
sha1sum (hex)	11bf75e973011d86b1039b707ed086b98deb5642
schema:url	https://doi.org/10.3389/fimmu.2019.02290
resource representing a document's title	Human Monoclonal Antibodies as Adjuvant Treatment of Chronic Hepatitis B Virus Infection
has PubMed Central identifier	PMC6773823
has PubMed identifier	31608071
schema:publication	Front Immunol
resource representing a document's body	covid:11bf75e973011d86b1039b707ed086b98deb5642#body_text
is schema:about of	named entity 'CHRONIC HEPATITIS B VIRUS INFECTION' named entity 'immunity' named entity 'adaptive' named entity 'infection' named entity 'Despite' named entity 'alternative' named entity 'Hepatitis B' named entity 'PROPERTIES' named entity 'CURRENTLY' named entity 'T CELLS' named entity 'BUT' named entity 'ANALOGS' named entity 'ALTERNATIVE' named entity 'ADVANTAGE' named entity '250' named entity 'PROBLEM' covid:arg/11bf75e973011d86b1039b707ed086b98deb5642 named entity 'SUPPRESS' named entity 'NEW' named entity 'SUBJECTS' named entity 'EXCESS' named entity 'SPECIFIC' named entity 'INTEREST' named entity 'SPECIFICITIES' named entity 'MORE THAN' named entity 'TO REDUCE' named entity 'HUMAN' named entity 'ANTIVIRAL DRUGS' named entity 'MONOCLONAL ANTIBODIES' named entity 'T-CELL' named entity 'HUMAN' named entity 'ADJUVANT TREATMENT' named entity 'MONOCLONAL ANTIBODIES' named entity 'HBV' named entity 'EFFECT' named entity 'ADAPTIVE IMMUNITY' named entity 'RESULTING FROM' named entity 'TO TAKE' named entity 'CHRONIC LIVER DISEASE' named entity 'OPTIMIZE' named entity 'EXPOSURE TO' named entity 'EFFECTIVE' named entity 'TREATMENT' named entity 'CHRONIC' named entity 'USED' named entity 'CLINICAL DEVELOPMENT' named entity 'BEING' named entity 'IMMUNITY' named entity 'VIRUS REPLICATION' named entity 'CIRRHOSIS' named entity 'EXHAUSTION' named entity 'ANTIGEN' named entity 'ADJUVANT TREATMENT' named entity 'RESPONSIBLE' named entity 'VACCINATED' named entity 'APPROACHES' named entity 'CONCENTRATIONS' named entity 'CD8' named entity 'PRECLINICAL' named entity 'FEATURE' named entity 'RECONSTITUTED' named entity 'INDIVIDUALS' named entity 'PERSISTENT' named entity 'ENVELOPE' named entity 'FULLY' named entity 'EARLY' named entity 'LOAD' named entity 'PROGRAMMED CELL DEATH PROTEIN 1' named entity 'MAB' named entity 'CONVALESCENT' named entity 'PROTEINS' named entity 'AVAILABLE' named entity 'EFFORT' named entity 'MILLION'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software